Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372615 | 0.85 | AXL (0.60) | AXLKMT2AGPR84MAP2K1LRRK2 | |
| SCHEMBL12188 | 0.85 | AXL (0.60) | AXLKMT2AGPR84MAP2K1LRRK2 | |
| Dimethylamine SCHEMBL8328446 | 0.81 | GPR84 (0.59) | AXLKMT2AGPR84MAP2K1LRRK2 | |
| SCHEMBL11883907 | 0.77 | MAP2K1 (0.61) | AXLKMT2AGPR84MAP2K1ADORA2A | |
| SCHEMBL2114977 | 0.75 | ADORA2A (0.67) | AXLKMT2AGPR84MAP2K1ADORA2A | |
| SCHEMBL28164021 | 0.74 | MAP2K1 (0.81) | AXLKMT2AMAP2K1ADORA2AMTNR1A | |
| SCHEMBL2638921 | 0.74 | ADORA2A (0.70) | AXLKMT2AGPR84MAP2K1ADORA2A | |
| SCHEMBL1665308 | 0.74 | MEN1 (0.67) | KMT2AMAP2K1ADORA2A | |
| SCHEMBL1820660 | 0.73 | ADORA2A (0.61) | AXLKMT2AGPR84MAP2K1ADORA2A | |
| Hydrochloric Acid SCHEMBL10655021 | 0.73 | ADORA2A (0.65) | AXLKMT2AGPR84MAP2K1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2008116139-A2 | N-HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1309565-B1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | AXL 3550/4885KMT2A 1797/4885GPR84 3768/4885 |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | AXL 724/4885KMT2A 1174/4885GPR84 4152/4885 |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | AXL 724/4885KMT2A 1174/4885GPR84 4152/4885 |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | AXL 724/4885KMT2A 1174/4885GPR84 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.